



PRECISION DIAGNOSTICS FOR LUNG CANCER

Help Sunnybrook provide earlier results and more personalized treatment options for patients with lung cancer

Anyone with lungs can get lung cancer. In fact, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death in Canada. Yet ongoing stigma persists because of the disease's close connection to smoking.

As a close supporter of Bev Moir, you know she feels a deep responsibility to amplify the message that lung cancer awareness must not only include risk reduction, but also early detection, treatment and research.

Sunnybrook continues to lead the way in developing more precise forms of diagnostic testing for lung and other cancers. But we need your help to enhance our testing capability and increase access for more patients.

Earlier results, earlier treatment

Liquid biopsy is a minimally invasive test that detects fragments of cancer cells circulating in the bloodstream. Liquid biopsy promises more information, less worry and earlier results for patients and their families.

This test is not yet widely accessible, especially for people with no history of smoking. Philanthropic support for clinical trials is the best way to demonstrate the efficacy of liquid biopsy for a wide range of cancer biomarkers while also increasing accessibility for patients.

Sunnybrook is excited to launch a new clinical trial exploring how liquid biopsy, in combination with precision radiation therapy, can better detect cancer cells and in early-stage cancer patients. Specifically, this will impact patients where a traditional, more invasive lung biopsy may be deemed too risky.

How you can help

Fundraisers like *Crush it with Bev!* play a powerful role in bringing the latest technologies, testing and treatments to patients at Sunnybrook to invent the future of lung cancer care.

Your support has helped Sunnybrook set the stage as we prepare to launch groundbreaking clinical research. Join us as we enter this next phase to validate liquid biopsy in the detection of lung cancer biomarkers and ensure more patients receive the care they need, when it matters most.

Your support at work

In 2022, your donations helped support clinical trials and train the next generation of specialists to advance lung cancer research.

A portion also helped Sunnybrook obtain the hardware needed to perform Rapid Onsite Cytology Evaluation (ROSE). ROSE allows clinicians to quickly determine whether a biopsy is positive for cancer. Crucially, this decreases the timeline to determine an appropriate course of action for treatment. Thank you.